We are live on ! Find out more
VU

Valence8 US Portfolio holdings

AUM $286M
1-Year Est. Return 22.37%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+22.37%
3 Year Est. Return
+53.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$241M
AUM Growth
+$49.2M
Cap. Flow
+$37.5M
Cap. Flow %
15.54%
Top 10 Hldgs %
93.09%
Holding
62
New
53
Increased
3
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
QUAL icon
iShares MSCI USA Quality Factor ETF
QUAL
+$6.32M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$5.41M
3
IQLT icon
iShares MSCI Intl Quality Factor ETF
IQLT
+$5.34M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$983K
5
BMY icon
Bristol-Myers Squibb
BMY
+$834K

Top Sells

Rank Stock Value
1
VTV icon
Vanguard Value ETF
VTV
+$565K
2
EWU icon
iShares MSCI United Kingdom ETF
EWU
+$275K
3
XLU icon
State Street Utilities Select Sector SPDR ETF
XLU
+$271K
4
XLP icon
State Street Consumer Staples Select Sector SPDR ETF
XLP
+$244K

Sector Composition

Rank Sector Weight
1 Healthcare 4.12%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QUAL icon
1
iShares MSCI USA Quality Factor ETF
QUAL
$46.1B
$60.5M 25.1%
337,472
+36,424
+12% +$6.32M
QQQ icon
2
Invesco QQQ Trust
QQQ
$466B
$43M 17.84%
88,149
+11,438
+15% +$5.41M
IQLT icon
3
iShares MSCI Intl Quality Factor ETF
IQLT
$13.6B
$42.6M 17.66%
1,026,290
+134,097
+15% +$5.34M
EFV icon
4
iShares MSCI EAFE Value ETF
EFV
$26B
$23M 9.53%
399,186
– –
VTV icon
5
Vanguard Value ETF
VTV
$186B
$16.9M 7%
96,630
-3,373
-3% -$565K
XLP icon
6
State Street Consumer Staples Select Sector SPDR ETF
XLP
$14.6B
$13.7M 5.69%
165,267
-3,033
-2% -$244K
EWU icon
7
iShares MSCI United Kingdom ETF
EWU
$4.02B
$7.83M 3.25%
209,344
-7,590
-3% -$275K
EWJ icon
8
iShares MSCI Japan ETF
EWJ
$21.5B
$7.77M 3.22%
108,634
– –
AZN icon
9
CALL
AstraZeneca
AZN
$262B
$4.99M 2.07%
+32,000
New +$5.17M
XLU icon
10
State Street Utilities Select Sector SPDR ETF
XLU
$23.5B
$4.2M 1.74%
103,880
-7,296
-7% -$271K
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.5B
$999K 0.41%
+8,969
New +$983K
BMY icon
12
Bristol-Myers Squibb
BMY
$124B
$920K 0.38%
+17,785
New +$834K
ASND icon
13
Ascendis Pharma A/S
ASND
$17.1B
$685K 0.28%
+4,585
New +$619K
AMGN icon
14
CALL
Amgen
AMGN
$198B
$644K 0.27%
+2,000
New +$654K
AMGN icon
15
PUT
Amgen
AMGN
$198B
$644K 0.27%
+2,000
New +$654K
SLNO
16
CALL
DELISTED
Soleno Therapeutics
SLNO
$631K 0.26%
+12,500
New +$598K
CRSP icon
17
CALL
CRISPR Therapeutics
CRSP
$4.71B
$615K 0.26%
+13,100
New +$665K
INSM icon
18
Insmed
INSM
$23.5B
$574K 0.24%
+7,865
New +$580K
INDV icon
19
Indivior Pharmaceuticals
INDV
$4.79B
$564K 0.23%
+57,293
New +$671K
LLY icon
20
Eli Lilly
LLY
$1.05T
$561K 0.23%
+633
New +$569K
ARGX icon
21
argenx
ARGX
$53.8B
$517K 0.21%
+953
New +$482K
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
$490K 0.2%
+9,706
New +$465K
INSM icon
23
CALL
Insmed
INSM
$23.5B
$482K 0.2%
+6,600
New +$487K
KROS icon
24
Keros Therapeutics
KROS
$211M
$466K 0.19%
+8,025
New +$396K
NVO
25
CALL
Novo Nordisk
NVO
$223B
$464K 0.19%
+3,900
New +$520K
1
2 3

Similar funds

A
Argentarii Cincinnati, Ohio $286M AUM 32.04% 1-Year Est. Return
MC
Muzinich & Co New York $286M AUM 21.05% 1-Year Est. Return
IRAG
Investment Research & Advisory Group Atlanta, Georgia $286M AUM 19.21% 1-Year Est. Return
4WM
44 Wealth Management Eugene, Oregon $286M AUM 18.78% 1-Year Est. Return
MAG
Mayfair Advisory Group Birmingham, Alabama $286M AUM 19.6% 1-Year Est. Return
HMP
HS Management Partners New York $286M AUM 2.97% 1-Year Est. Return
SIIL
Sinvest Investments II Ltd Nassau, New Providence $286M AUM
LCM
Leisure Capital Management Costa Mesa, California $286M AUM 26.75% 1-Year Est. Return

Valence8 US's Q3 2024 Portfolio in Review

As of Q3 2024, Valence8 US held 62 positions worth $241M, up 26% from $192M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Valence8 US deployed $37.5M of net new capital in Q3 2024, opening 53 new positions and adding to 3 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 8,969 shares worth $999K.

By sector, the portfolio is most concentrated in Healthcare at 4.1% of assets, followed by Financials.

On the sell side, the largest reduction was Vanguard Value ETF, an estimated $565K trimmed.

  • Valence8 US's largest Q3 2024 buy was Jazz Pharmaceuticals: 8,969 shares worth $999K.
  • Valence8 US added most to iShares MSCI USA Quality Factor ETF in Q3 2024, an estimated $6.32M increase.
  • Valence8 US's biggest Q3 2024 reduction was Vanguard Value ETF, cutting an estimated $565K.
  • Valence8 US's ten largest holdings make up 93% of its $241M portfolio in Q3 2024.
  • Valence8 US opened 53 new positions and closed 0 in Q3 2024.
  • Valence8 US's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Valence8 US's 13F filing for Q3 2024, filed 12 Nov 2024.